FDA approves another in a new class of cholesterol drugs
Amgen's Repatha joins Sanofi's Praluent; but potency of medications raises a key question
New York
THE US Food and Drug Administration (FDA) has approved the second drug in a novel class of powerful cholesterol-lowering medications.
The new drug, Repatha, made by Amgen, is intended for people with extremely high cholesterol levels and those with heart disease who cannot sufficiently lower their cholesterol levels with statins and other therapies. Repatha will cost US$14,100 per year.
The two drugs are the first highly effective c…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Prada’s sales up 16% in first quarter as Miu Miu shines
Toymaker Hasbro posts quarterly profit beat, slower sales decline
Hilton lifts 2024 profit forecast on international travel demand
China knockoff raid jolts a global throng of fake-fashion influencers
Roche cuts pipeline after research setbacks and sales drop
Cordlife customers push for legal action